Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients

Bibliography

• Pfizer Ltd. Enbrel: summary of product characteristics
   Google Scholar
• Weinblatt ME, Bathon JM, Kremer JM, et al. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care Res 2011;63:373-82
   PubMed Web of Science ®Google Scholar
• Johnson CJ, Reilly KM, Murray KM. Etanercept in juvenile rheumatoid arthritis. Ann Pharmacother 2001;35:464-71
   PubMed Web of Science ®Google Scholar
• Klareskog L, Gaubitz M, Rodríguez-Valverde V, et al. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011;29:238-47
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Haibel H, Fritz C, et al. Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther 2013;15:R67
   PubMed Web of Science ®Google Scholar
• Kobelt G, Lekander I, Lang A, et al. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment. Int J Technol Assess Health Care 2011;27:193-200
   PubMed Web of Science ®Google Scholar
• Raffeiner B, Botsios C, Sfriso P, et al. The effects of low dose etanercept on disease control and radiographic progression in moderate to severe rheumatoid arthritis. Arthritis Rheum 2010;62:S120
   Google Scholar
• Cantini F, Niccoli L, Cassarà E, et al. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study. Biologics 2013;7:1-6
   PubMedGoogle Scholar
• Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24
   PubMed Web of Science ®Google Scholar
• van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8
   PubMed Web of Science ®Google Scholar
• Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69:976-86
   PubMed Web of Science ®Google Scholar
• Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12
   PubMed Web of Science ®Google Scholar
• Berthelot JM, Varin S, Cormier G, et al. 25 mg etanercept once weekly in rheumatoid arthritis and spondylarthropathy. Joint Bone Spine 2007;74:144-7
   PubMed Web of Science ®Google Scholar
• Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009;131:308-16
   PubMed Web of Science ®Google Scholar
• Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomized controlled trial. Lancet 2013;381:918-29
   PubMed Web of Science ®Google Scholar
• Botsios C, Furlan A, Otsuni P, et al. Effects of low-dose etanercept in maintaining das-remission previously achieved with standard-dose in patients with rheumatoid arthritis. Ann Rheum Dis 2009;66(Suppl II):54
   Google Scholar
• Navarro-Compan V, Moreira V, Ariza-Ariza R, et al. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol 2011;30:993-6
   PubMed Web of Science ®Google Scholar
• De Stefano R, Frati E, De Quattro D, et al. Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients. Clin Rheumatol 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Inciarte-Mundo J, Hernández MV, Rosario V, et al. Reduction of biological agent dose in rheumatic diseases: Descriptive analysis of 153 patients in clinical practice conditions. Reumatol Clin 2013. [Epub ahead of print]
   Google Scholar
• Navarro-Compán V, Moreira Navarrete V, Ariza Ariza R, et al. Costes farmacológicos asociados al ajuste de dosis de etanercept en pacientes con espondilitis anquilosante en remisión. 56 Congreso SEFH; 2011
   Google Scholar
• Rubio-Terrés C, Ordovás Baines JP, Pla Poblador R, et al. Use and cost of biological disease-modifying anti-rheumatic drugs in Spain (PRAXIS study). Farm Hosp 2007;31:78-92
   PubMedGoogle Scholar